Jordana E Hoppe1, Brandie D Wagner2, J Kirk Harris3, Steven M Rowe4, Sonya L Heltshe5, Emily M DeBoer3, Scott D Sagel3. 1. Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: jordana.hoppe@childrenscolorado.org. 2. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 3. Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 4. Department of Medicine, Pediatrics and Cell Developmental and Integrative Biology, University of Alabama Birmingham, Birmingham, AL, England. 5. Department of Pediatrics, University of Washington, Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle, WA, United States.
Abstract
BACKGROUND: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator for people with CF and the G551D mutation. We aimed to investigate the biology of CFTR modulation and systemic effects of CFTR restoration by examining changes in circulating measurements of inflammation and growth and novel proteins with ivacaftor treatment. METHODS: Blood samples from 64 CF subjects with G551D-CFTR were analyzed for inflammatory and growth-related proteins at baseline, 1 and 6 months after ivacaftor initiation. In 30 subjects, plasma was assayed for 1,322 proteins using the SomaScan proteomic platform at baseline and 6 months post-ivacaftor. Correlations with clinical outcomes were assessed. MEASUREMENTS AND MAIN RESULTS: Significant reductions in high mobility group box-1 protein (HMGB-1), calprotectin, serum amyloid A, and granulocyte colony-stimulating factor (G-CSF), and an increase in insulin-like growth factor (IGF-1) occurred 1 month after ivacaftor. This treatment effect was sustained at 6 months for HMGB-1 and calprotectin. Correcting for multiple comparisons in the proteomic analysis, 9 proteins (albumin, afamin, leptin, trypsin, pancreatic stone protein [PSP], pituitary adenylate cyclase-activating polypeptide-38, repulsive guidance molecule A [RGMA], calreticulin, GTPase KRas) changed significantly with ivacaftor. Proteins changing with treatment are involved in lipid digestion and transport and extracellular matrix organization biological processes. Reductions in calprotectin and G-CSF and increases in calreticulin, and RGMA correlated with improved lung function, while increasing IGF-1, leptin and afamin and decreasing PSP correlated with increased weight. CONCLUSIONS: Ivacaftor led to changes in inflammatory, lipid digestion, and extracellular matrix proteins, lending insights into the extrapulmonary effects of CFTR modulation.
BACKGROUND: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator for people with CF and the G551D mutation. We aimed to investigate the biology of CFTR modulation and systemic effects of CFTR restoration by examining changes in circulating measurements of inflammation and growth and novel proteins with ivacaftor treatment. METHODS: Blood samples from 64 CF subjects with G551D-CFTR were analyzed for inflammatory and growth-related proteins at baseline, 1 and 6 months after ivacaftor initiation. In 30 subjects, plasma was assayed for 1,322 proteins using the SomaScan proteomic platform at baseline and 6 months post-ivacaftor. Correlations with clinical outcomes were assessed. MEASUREMENTS AND MAIN RESULTS: Significant reductions in high mobility group box-1 protein (HMGB-1), calprotectin, serum amyloid A, and granulocyte colony-stimulating factor (G-CSF), and an increase in insulin-like growth factor (IGF-1) occurred 1 month after ivacaftor. This treatment effect was sustained at 6 months for HMGB-1 and calprotectin. Correcting for multiple comparisons in the proteomic analysis, 9 proteins (albumin, afamin, leptin, trypsin, pancreatic stone protein [PSP], pituitary adenylate cyclase-activating polypeptide-38, repulsive guidance molecule A [RGMA], calreticulin, GTPase KRas) changed significantly with ivacaftor. Proteins changing with treatment are involved in lipid digestion and transport and extracellular matrix organization biological processes. Reductions in calprotectin and G-CSF and increases in calreticulin, and RGMA correlated with improved lung function, while increasing IGF-1, leptin and afamin and decreasing PSP correlated with increased weight. CONCLUSIONS: Ivacaftor led to changes in inflammatory, lipid digestion, and extracellular matrix proteins, lending insights into the extrapulmonary effects of CFTR modulation.
Authors: Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead Journal: Chest Date: 2012-11 Impact factor: 9.410
Authors: Andrea Kelly; Diva D De Leon; Saba Sheikh; Devaney Camburn; Christina Kubrak; Amy J Peleckis; Darko Stefanovski; Denis Hadjiliadis; Michael R Rickels; Ronald C Rubenstein Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405
Authors: Jane C Davies; Steve Cunningham; William T Harris; Allen Lapey; Warren E Regelmann; Gregory S Sawicki; Kevin W Southern; Sarah Robertson; Yulia Green; Jon Cooke; Margaret Rosenfeld Journal: Lancet Respir Med Date: 2016-01-21 Impact factor: 30.700
Authors: Kerstin Tiringer; Angela Treis; Petra Fucik; Mia Gona; Saskia Gruber; Sabine Renner; Eleonora Dehlink; Edith Nachbaur; Friedrich Horak; Peter Jaksch; Gerd Döring; Reto Crameri; Andreas Jung; Mascha K Rochat; Marcus Hörmann; Andreas Spittler; Walter Klepetko; Cezmi A Akdis; Zsolt Szépfalusi; Thomas Frischer; Thomas Eiwegger Journal: Am J Respir Crit Care Med Date: 2013-01-10 Impact factor: 21.405